Physician profile
John W Winzenread
NPI 1437136645
$1,598.38
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,309 · 2020: $269 · 2023: $19.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $275.06 | 2019-2020 | |
| Novo Nordisk INC | $162.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $138.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.07 | 2019 | |
| Merck Sharp & Dohme LLC | $112.14 | 2019 | |
| Glaxosmithkline, LLC. | $73.96 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.87 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $64.03 | 2019 | |
| Astellas Pharma US INC | $59.62 | 2019-2020 | |
| Allergan, INC. | $58.57 | 2019-2020 | |
| Amarin Pharma, INC. | $55.84 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $43.43 | 2019-2020 | |
| Shire North American Group INC | $39.86 | 2019 | |
| Pfizer INC. | $37.90 | 2019-2020 | |
| Radius Health, INC. | $33.48 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.21 | 2019 | |
| Boston Scientific Corporation | $24.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.93 | 2019 | |
| Exact Sciences Corporation | $19.69 | 2023 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $19.40 | 2020 | |
| Genentech USA, INC. | $18.79 | 2019 | |
| Valeritas, INC. | $18.39 | 2019 | |
| Abbvie INC. | $18.28 | 2020 | |
| Sanofi Pasteur INC. | $16.37 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.75 | 2019 | |
| Lilly USA, LLC | $13.33 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.62 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Winzenread listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.